Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Innate Pharma SA ( (FR:IPH) ) is now available.
Innate Pharma S.A., a clinical-stage biotech specializing in cancer immunotherapies and next‑generation antibody drugs, reported on April 2, 2026 that it has filed its 2025 Universal Registration Document with France’s Autorité des Marchés Financiers. The filing, made on April 1, 2026, bundles the company’s annual financial report, management report, corporate governance report and statutory auditors’ report for the year ended December 31, 2025.
On the same day, Innate Pharma also reported it had submitted its Form 20‑F annual report for 2025 to the U.S. Securities and Exchange Commission on April 1, 2026, making detailed regulatory and financial disclosures available to both European and U.S. investors. The twin filings underscore the company’s commitment to transparency and compliance across its dual listings, providing stakeholders with updated insight into its operations, governance and risk profile after the 2025 financial year.
The most recent analyst rating on (FR:IPH) stock is a Sell with a EUR1.00 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. Leveraging expertise in antibody engineering and novel target identification, it is advancing next‑generation antibody therapeutics, including IPH4502, lacutamab and monalizumab, and operates through partnerships with groups such as Sanofi and AstraZeneca.
Headquartered in Marseille, France, with a U.S. office in Rockville, Maryland, Innate Pharma targets areas of high unmet medical need in solid tumors and lymphomas. The company is listed on Euronext Paris under the ticker IPH and on Nasdaq under IPHA, giving it access to both European and U.S. capital markets for its immuno‑oncology pipeline.
Average Trading Volume: 183,275
Technical Sentiment Signal: Sell
Current Market Cap: €105.4M
For a thorough assessment of IPH stock, go to TipRanks’ Stock Analysis page.